Aspira Announces Second Quarter 2025 Financial Results and Provides Business Update
Aspira Women's Health (OTCQB:AWHL) reported its Q2 2025 financial results, showing stable performance amid significant business model transformation. Total product revenue reached $2.404 million in Q2 2025, compared to $2.423 million in Q2 2024. The company achieved a 12% year-over-year increase in average unit prices for its commercial portfolio.
Key achievements include a 156% increase in sales per FTE, improved gross margins of 66.1% (up from 57.6%), and a 41% reduction in operating cash burn. Operating expenses decreased by 31% to $8.1 million for H1 2025. The company maintained revenue stability despite reducing its sales team from 19 to 7 specialists, while focusing on relationships with large healthcare systems and IDNs.
Aspira Women's Health (OTCQB:AWHL) ha comunicato i risultati del Q2 2025, mostrando una performance stabile in un contesto di significativa trasformazione del modello di business. I ricavi totali da prodotti sono stati di $2.404 million nel Q2 2025, rispetto a $2.423 million nel Q2 2024. L'azienda ha registrato un incremento annuo del 12% nel prezzo medio per unit脿 del portafoglio commerciale.
Tra i risultati chiave figurano un aumento del 156% delle vendite per FTE, un miglioramento del margine lordo al 66,1% (da 57,6%) e una riduzione del 41% del burn di cassa operativo. Le spese operative sono diminuite del 31%, attestandosi a $8.1 milioni nel primo semestre 2025. L'azienda ha mantenuto la stabilit脿 dei ricavi nonostante la riduzione del team commerciale da 19 a 7 specialisti, concentrandosi sulle relazioni con grandi sistemi sanitari e IDN.
Aspira Women's Health (OTCQB:AWHL) inform贸 sus resultados del Q2 2025, mostrando un desempe帽o estable en medio de una importante transformaci贸n del modelo de negocio. Los ingresos totales por productos alcanzaron $2.404 million en el Q2 2025, frente a $2.423 million en el Q2 2024. La compa帽铆a logr贸 un aumento interanual del 12% en los precios medios por unidad de su cartera comercial.
Logros clave incluyen un
Aspira Women's Health (OTCQB:AWHL)電� 牍勳雼堨姢 氇嵏鞚� 雽�雽�鞝� 鞝勴櫂 靻嶌棎靹滊弰 鞎堨爼鞝侅澑 鞁れ爜鞚� 氤挫澊氅� 2025雲� 2攵勱赴 鞁れ爜鞚� 氚滍憸頄堨姷雼堧嫟. 齑� 鞝滍拡 毵れ稖鞚� 2025雲� 2攵勱赴鞐� $2.404 million鞚� 旮半頄堨溂氅�, 2024雲� 2攵勱赴鞚� $2.423 million瓿� 鞙犾偓頃� 靾橃鞚挫棃鞀惦媹雼�. 靸侅梾 韽姼韽措Μ鞓れ潣 雼渼雼� 韽夑窢 臧�瓴╈潃 鞝勲厔 雽�牍� 12% 歃濌皜頄堨姷雼堧嫟.
欤检殧 靹标臣搿滊姅 FTE雼� 毵れ稖 156% 歃濌皜, 66.1%(鞝勲厔 57.6%鞐愳劀)搿� 臧滌劆霅� 齑濎澊鞚惦, 攴鸽Μ瓿� 鞓侅梾 順勱笀 靻岇 41% 臧愳唽臧� 韽暔霅╇媹雼�. 鞓侅梾 牍勳毄鞚� 2025雲� 靸侂皹旮办棎 31% 臧愳唽頃橃棳 $8.1 million鞚挫棃鞙茧┌, 鞓侅梾韺�鞚� 19氇呾棎靹� 7氇呾潣 鞝勲鞚鸽牓鞙茧 於曥唽頄堨潓鞐愲弰 欤检殧 鞚橂 鞁滌姢韰� 氚� IDN瓿检潣 甏�瓿勳棎 歆戩頃橂┐靹� 毵れ稖 鞎堨爼靹膘潉 鞙犾頄堨姷雼堧嫟.
Aspira Women's Health (OTCQB:AWHL) a publi茅 ses r茅sultats du T2 2025, affichant une performance stable malgr茅 une transformation importante de son mod猫le 茅conomique. Le chiffre d'affaires produit total s'est 茅lev茅 脿 $2.404 million au T2 2025, contre $2.423 million au T2 2024. L'entreprise a r茅alis茅 une hausse annuelle de 12% du prix moyen par unit茅 de son portefeuille commercial.
Parmi les r茅alisations cl茅s figurent une augmentation de 156% des ventes par ETP, une am茅lioration de la marge brute 脿 66,1% (contre 57,6%) et une r茅duction de 41% du burn de tr茅sorerie op茅rationnel. Les d茅penses d'exploitation ont diminu茅 de 31%, pour s'茅tablir 脿 $8.1 million au premier semestre 2025. La soci茅t茅 a maintenu la stabilit茅 des revenus malgr茅 la r茅duction de son 茅quipe commerciale de 19 脿 7 sp茅cialistes, en se focalisant sur les relations avec de grands syst猫mes de sant茅 et les IDN.
Aspira Women's Health (OTCQB:AWHL) meldete die Finanzergebnisse f眉r das 2. Quartal 2025 und zeigte dabei eine stabile Entwicklung trotz umfangreicher Umstrukturierungen des Gesch盲ftsmodells. Der Gesamtproduktumsatz belief sich im Q2 2025 auf $2.404 million gegen眉ber $2.423 million im Q2 2024. Das Unternehmen erzielte einen jahres眉bergreifenden Anstieg von 12% beim durchschnittlichen St眉ckpreis seines kommerziellen Portfolios.
Wesentliche Erfolge sind ein 156%iger Anstieg der Verk盲ufe pro FTE, eine verbesserte Bruttomarge von 66,1% (vorher 57,6%) und eine 41%ige Reduktion des operativen Cash-Burns. Die Betriebskosten sanken im H1 2025 um 31% auf $8.1 million. Die Ums盲tze blieben stabil, obwohl das Vertriebsteam von 19 auf 7 Spezialisten reduziert wurde, wobei der Fokus auf Beziehungen zu gro脽en Gesundheitssystemen und IDNs liegt.
- None.
- None.
Insights
Aspira's Q2 shows improved operational efficiency and margins despite flat revenue, significantly reducing cash burn by 41%.
Aspira Women's Health delivered mixed Q2 2025 results that highlight meaningful operational improvements amid strategic restructuring. The company reported
The strategic pivot toward targeting large healthcare systems and Integrated Delivery Networks (IDNs) is showing early signs of success through pricing improvements. Average unit prices increased
Most impressive is the dramatic improvement in financial efficiency. Gross margin expanded significantly to
The balance sheet is also strengthening, with current liabilities reduced by
AUSTIN, TX / / August 13, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and six months ended June 30, 2025. The Company also reported early progress under its new leadership team.
Second Quarter Highlights:
Aspira reported total product revenue of
Product revenue remained stable despite a very significant reset of Aspira's business model and market strategies beginning in the first quarter of 2025, with continuing substantial changes well into the second quarter. Through this transformation of our strategy, commercial model, and resources, Aspira is heavily focusing on relationships with leading large scale health care systems, as well as Integrated Delivery Networks ("IDNs"). The Company's Directors and Management believe this will sharply improve the Company's efficiency, operating performance, and long-term profitability. Notably, the Company's specialist field sales team delivered these second quarter results with a team of 7 as compared to a team of 19 in the same period of 2024.
Key financial highlights for the six months ended June 30, 2025 are summarized below:
Revenue Growth: The Company generated approximately
$4.68 3 million of revenue for the six months ending June 30, 2025, compared to$4.57 6 million in the same period in 2024. The2.3% increase was primarily driven by a10.3% increase in the average unit price per test, partially offset by a7.3% decrease in the number of tests sold. We have witnessed transitional test volume shifts that are commonly seen when marketing strategy and team changes are implemented. These changes were completed within the June quarter. As a sales productivity metric, the Company tracks revenues generated per full-time equivalent salesperson ("FTE"). Due to the marketing strategy changes and large health care system emphasis in the second quarter of 2025, the Company realized a156% increase in sales per FTE compared to the second quarter of 2024.
Gross Profit and Margin Improvement: Grossprofit increased to approximately
$3.1 million in the first half of 2025, as compared to$2.6 million in the same period in 2024, representing a17.4% increase. Gross margins were66.1% , as compared to57.6% in the same period of the prior year. The increase in gross profit and improved margins was primarily the result of an adjustment to prior quarter revenue due to collections in excess of previously recognized revenue, as well as improved profitability of the OvaWatch product line. Revenue is initially estimated based on expectations of account performance, then is adjusted based on actual collections.
Reduction in Operating Expenses: Total operating expenses decreased to
$8.1 million for the first six months of 2025, compared to$11.7 million for the same period in the prior year, representing a$3.6 million , or31% decrease. The decrease was primarily due to a decrease in selling expenses of$2.3 million , combined with a$1.1 million decrease in general and administrative expenses and a$0.2 million decrease in research and development expenses. Reductions in headcount and other cost containment measures were primary drivers in the reduction of these expenses.
Reduced Burn Rate: Cash used in operations was
$4.8 million for the six months ended June 30, 2025, as compared to$8.2 million in the six months ended June 30, 2024. This represents a41% reduction in operating cash burn. This improvement is primarily due to the new leadership team's focus on cost control and improved productivity.
Improved Balance Sheet: The Company reported
$4.1 million in current liabilities, of which$3.6 million was trade payables or accrued liabilities as of June 30, 2025. This represents a$1.4 million , or25.1% decrease from the$5.5 million in current liabilities reported as of December 31, 2024. The reduction was principally the result of a$0.4 million reduction in payables and a$0.6 million reduction in accrued liabilities, which was primarily related to payroll and benefits as well as a one-time reduction in accruals.
"My top priority in the second quarter of 2025 was to continue driving the commercial team's efficiencies, to further reduce operating expenses and outstanding liabilities, and to strengthen Aspira's overall financial position" commented Mike Buhle, who was appointed Chief Executive Officer of Aspira in January 2025. He continued, "Through June 30, 2025, we delivered notable gains in sales productivity and increase our gross profit margin by
"In parallel with enhancing operational performance, we are aggressively working on achieving our research and development timeline for ENDOInform鈩�. We remain committed to completing our R&D milestones and expect to provide material updates on this project by the end of 2025," concluded Mr. Buhle.
"The Board of Directors is excited to see the new strategy and operating initiatives take hold. We believe the Company is entering entirely unprecedented ground in advancing the Company's key women's health diagnostic tools in both ovarian cancer and endometriosis," commented Jack Fraser, Chairman of the Board of Directors.
The following table summarizes the key financial metrics of the three and six months ended June 30, 2025 and 2024.
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Total Revenue | $ | 2,404 | $ | 2,423 | $ | 4,683 | $ | 4,576 | ||||||||
Gross Margin | 63.8 | % | 58.6 | % | 66.1 | % | 57.6 | % | ||||||||
Total OvaSuite Volume | 5,728 | 6,471 | 11,407 | 12,300 | ||||||||||||
Total AUP | $ | 420 | $ | 374 | $ | 411 | $ | 372 | ||||||||
About Aspira Women's Health Inc.
Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.鈥�疧vaWatch and Ova1Plus庐 are offered to clinicians as OvaSuite. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of
Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.
Forward-Looking Statements鈥�
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "designed to," "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission (SEC), including those factors identified as "Risk Factors" in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.鈥�
Investor Relations Contact:鈥�
Aspira Women's Health Inc.
Condensed Consolidated Balance Sheets (unaudited)
(Amounts in Thousands, Except Share and Par Value Amounts)
June 30, | December 31, | |||||||
2025 | 2024 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 1,545 | $ | 1,769 | ||||
Accounts receivable, net of reserves of | 1,278 | 990 | ||||||
Prepaid expenses and other current assets | 590 | 1,098 | ||||||
Inventories | 273 | 326 | ||||||
Total current assets | 3,686 | 4,183 | ||||||
Property and equipment, net | 44 | 69 | ||||||
Right-of-use assets | 1,077 | 1,194 | ||||||
Other assets | 127 | 45 | ||||||
Total assets | $ | 4,934 | $ | 5,491 | ||||
Liabilities and Stockholders' Deficit | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,743 | $ | 2,173 | ||||
Accrued liabilities | 1,829 | 2,445 | ||||||
Current portion of long-term debt | 232 | 229 | ||||||
Short-term debt | 154 | 614 | ||||||
Current maturities of lease liabilities | 140 | 7 | ||||||
Total current liabilities | 4,098 | 5,468 | ||||||
Non-current liabilities: | ||||||||
Long-term debt | 1,160 | 1,278 | ||||||
Non-current maturities of lease liabilities | 1,121 | 1,248 | ||||||
Warrant liabilities | 1,240 | 60 | ||||||
Total liabilities | 7,619 | 8,054 | ||||||
Commitments and contingencies | ||||||||
Stockholders' deficit: | ||||||||
Common stock, par value | 36 | 17 | ||||||
Additional paid-in capital | 533,195 | 528,817 | ||||||
Accumulated deficit | (535,916 | ) | (531,397 | ) | ||||
Total stockholders' deficit | (2,685 | ) | (2,563 | ) | ||||
Total liabilities and stockholders' deficit | $ | 4,934 | $ | 5,491 | ||||
Aspira Women's Health Inc.
Condensed Consolidated Statements of Operations (unaudited)
(Amounts in Thousands, Except Share and Par Value Amounts)
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Revenue: | ||||||||||||||||
Product | $ | 2,404 | $ | 2,423 | $ | 4,683 | $ | 4,576 | ||||||||
Total revenue | 2,404 | 2,423 | 4,683 | 4,576 | ||||||||||||
Cost of revenue: | ||||||||||||||||
Product | 870 | 1,002 | 1,589 | 1,941 | ||||||||||||
Total cost of revenue | 870 | 1,002 | 1,589 | 1,941 | ||||||||||||
Gross profit | 1,534 | 1,421 | 3,094 | 2,635 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 704 | 952 | 1,677 | 1,858 | ||||||||||||
Sales and marketing | 679 | 2,137 | 1,765 | 4,026 | ||||||||||||
General and administrative | 1,961 | 2,725 | 4,702 | 5,854 | ||||||||||||
Total operating expenses | 3,344 | 5,814 | 8,144 | 11,738 | ||||||||||||
Loss from operations | (1,810 | ) | (4,393 | ) | (5,050 | ) | (9,103 | ) | ||||||||
Other (expense) income, net: | ||||||||||||||||
Change in fair value of warrant liabilities | (624 | ) | 889 | 297 | 1,140 | |||||||||||
Change in fair value of convertible notes | - | - | 170 | - | ||||||||||||
Loss upon issuance of Convertible Notes carried at fair value | - | - | (1,198 | ) | - | |||||||||||
Interest expense, net | (13 | ) | (10 | ) | (27 | ) | (15 | ) | ||||||||
Other (expense) income, net | (219 | ) | (16 | ) | 1,289 | (181 | ) | |||||||||
Total other (expense) income, net | (856 | ) | 863 | 531 | 944 | |||||||||||
Net loss | $ | (2,666 | ) | $ | (3,530 | ) | $ | (4,519 | ) | $ | (8,159 | ) | ||||
Net loss per share - basic and diluted | $ | (0.07 | ) | $ | (0.28 | ) | $ | (0.16 | ) | $ | (0.67 | ) | ||||
Weighted average common shares used to compute basic and diluted net loss per common share | 35,564,032 | 12,518,725 | 28,579,132 | 12,181,481 | ||||||||||||
SOURCE: Aspira Women's Health
View the original on ACCESS Newswire
